Refer to the case study. Many standards apply to the design of buildings, including windows and doors. The new ISO 23045: 2008 establishes specific guidelines applicable to the design of buildings, to improve energy efficiency. To this end, the ISO covers the choice of the raw materials and components used, the location of the building, and the energy sources used. In theory, the ISO enables the transmission and sharing of information about a building's energy efficiency by standardizing its energy statement. It also defines objectives specific to each construction project from the design stage onwards (source: ISO Standards habitat). In addition, companies use independent inspection and certification to prove the increased performance of their products, and to act as a guarantee of their quality. Thus, the NF and CSTB labels ensure compliance for window manufacture, with minimum levels of quality and standards concerning air - and water-tightness, and wind resistance. Such certification of PVC joinery allows consumers to assess manufacturing quality with respect to those three factors.

Question 31 What is the cause of Pott's disease?

Question 32 One thing that often baffles me is that patients with systemic lupus erythematosus often suffer recurrent thrombosis due to lupus anticoagulants (antiphospholipid syndrome). How can an anticoagulant cause thrombosis?

Question 33 Are elevated homocysteine levels an independent risk factor for progression of systemic lupus erythematosus (SLE)/scleroderma? Kindly suggest some references if possible.

Question 34 1. What are the indicators of remission in systemic lupus erythematosus (SLE)? Is it the normalization of erythrocyte sedimentation rate (ESR) and the disappearance of antinuclear antibodies (ANA) and other antibodies, or is it clinical improvement? 2. During remission of SLE, ANA and other antibodies disappear?

Question 35 When should the use of cyclophosphamide in systemic lupus erythematosus (SLE) be commenced? What is the correct and safe dosage of cyclophosphamide?

Question 36 1. Given the benefits of dexamethasone, which lacks any mineralocorticoid activity, why is this not prescribed in your book for diseases that require long-term steroid therapy, such as systemic lupus erythematosus or giant cell arteritis? 2. Does dexamethasone have more serious adverse effects than prednisolone? Why is it not generally preferred?

Question 37 Would an elevated C-reactive protein (CRP) level, in association with a high erythrocyte sedimentation rate (ESR) and in the absence of infection and serositis, exclude the diagnosis of systemic lupus erythematosus?

Question 38 How do steroids precipitate a crisis in patients with systemic sclerosis?

Question 39 Are neck and face muscles commonly affected in poly- and dermatomyositis? Does this differ from the muscles that are affected with myasthenia gravis?

Question 40 1. In dermatomyositis, what is the shawl sign? 2. How frequently is dermatomyositis associated with Gottron's papules?